Chimerix recently received positive results concerning smallpox drug brincidofovir, which has been able to act against smallpox in animal subjects.
The results were presented at the ASM Biodefense and Emerging Diseases Research Meeting that was held in Arlington, Virginia.
“Data from this pivotal animal model study support the potential to advance brincidofovir as a medical countermeasure for smallpox,” Dr. Michelle Berrey, president and CEO of Chimerix, said. “There is currently no antiviral approved to treat smallpox, considered a Category A Priority Pathogen by the National Institute of Allergy and Infectious Diseases (NIAID). We look forward to working closely with the FDA and BARDA to contribute to the U.S. national security and public health preparedness.”
The study was conducted on animals in a lab under the Food and Drug Administration’s Animal Efficacy Rule. Animals were injected with the infection, then received brincidofovir or a placebo after 24, 48 or 72 hours.
Animals that received the drug right away had a survival rate of 100 percent. Animals that received the drug after a 24 or 48-hour period had a 93 percent survival rate. The survival rate for animals that received the placebo was less than 50 percent.
The drug has yet to be tested on humans.